2 Red Flags for Biogen's Future

Biotech giant Biogen (NASDAQ: BIIB) has generated many headlines in the past couple of years, largely due to its Alzheimer's disease (AD) therapy, Aduhelm, and that drug's controversial path to approval in the U.S. However, this landmark regulatory win hasn't been enough to save Biogen's performance.

The company's shares have significantly lagged the market in the past year. Unfortunately, it could get worse before it gets better for the biotech. Let's look at two red flags that Biogen is currently facing and discuss whether it is worth it to purchase the company's shares right now. 

Continue reading

Source Fool.com